(GDP) by 2010. Today only two Member States, Sweden and Finland, have reached this goal. 4. The Commission is constantly looking at ways to improve, support and speed-up the drug development process. The EDCTP is an example of this for poverty related diseases. The proposed establishment of a joint technology initiative (JTI) for innovative medicines, with a specific aim to reduce the drug development time and costs, is another example. In addition, the Commission is looking into a range of incentives to encourage more investment in the research and development of what one may refer to as ‘economically orphan medicines’. There is a strong commitment at the highest level for taking this initiative further and looking at proposals which include further examination of better access to venture capital, low-cost loans, tax credits, guaranteed markets and the extension of patent rights and/or market exclusivity.